phone icon  Int'l : +1-503-894-6022
Allied Market Research
0
Shopping Cart is Empty..
$ 0

Companion diagnostics are in-vitro diagnostics that provide information about therapeutic responses of patients for a specific treatment. Companion diagnostics market is still nascent, and it is projected to reach $3.5 billion by 2020 from a base value of $1.1 billion in 2013, growing at a CAGR of 20% during 2014 to 2020. The global companion diagnostic market is segmented based on indication, technology and geography (North America, Europe, Asia Pacific and LAMEA). Geographically, LAMEA is the fastest growing region. The key drivers for this market are the increase in the discovery of biomarkers and co-development of drug and corresponding diagnostic. However, cost associated with developing drugs could impede the growth of this market. Opportunities for this market lie in developing companion diagnostics for various central nervous system conditions and hereditary conditions.

Companion Diagnostics Indication Market Analysis

Companion diagnostics is segmented on the basis of its use for indications such as oncology, cardiovascular conditions, central nervous system indications, inflammation and virology. Oncology is the highest revenue generating segment, as majority of the companion diagnostics have been developed for detection of various cancer biomarkers. The key driver for this market is an increase in research and development of targeted drugs, which require a corresponding companion diagnostic.

Companion Diagnostics Technology Market Analysis

Companion diagnostics technology market is segmented into Immunohistochemistry and Molecular diagnostics. Molecular diagnostics would be the fastest growing and highest revenue generator, mainly due to the use of techniques such as real time PCR, In Situ Hybridization and next generation sequencing. Other factors contributing to the growth is technological advancements in molecular diagnostics, which has resulted in increased accuracy and precision and also reduced cost of testing using these methods.

Companion Diagnostics Geography Market Analysis

Companion Diagnostics market has been segmented geographically into North America, Europe, Asia Pacific and LAMEA. North America has the major market share of 43.97% followed by Europe, which accounted for about 38% of the overall CD market in 2013. North America and Europe together accounted for over 82% in the global CD market in 2013 and they would continue to be the major markets through 2020. This is mainly due to the increasing incidence of cancer and other diseases and higher health care awareness in these regions.

Competitive Analysis

A study of some of the key players has showed that majority of the companies in this market are focusing on collaborations with drug companies. Companion diagnostics is a emerging market and companies are collaborating with drug companies to develop companion diagnostics for their pipeline drugs, which are in developing phase. Approvals for companion diagnostics are the second most popular strategy. Companies profiled in this report include Dako (Agilent Technologies), Qiagen, Roche, Abbott Laboratories, Inc., Ventana Medical Systems, bioMerieux, Myriad Genetics, Inc., Resonance Health Ltd., Leica Microsystems, and Life Technologies.

High Level Analysis

The report is focusing on the trends in technology and diagnosis of various indications, which are driving the growth of the companion diagnostics market. Analysis of the market based on porters five force model shows that the bargaining power of the suppliers is high as the products produced are highly differentiated. The threat of new entrants is low as significant research and development is required for developing diagnostic tests. Apart from the R&D requirements, the investment required is also high. These factors make it difficult for new companies to enter the market. The threat of substitutes is low in this market as companion diagnostics are developed for specific biomarkers and the products are highly differentiated. Competition in this market is moderate as the market is still emerging and there are a few companies in the market. Government regulations are favoring use of companion diagnostics for determining a particular treatment. Companies are focusing on collaborations with pharmaceutical companies as a key strategy to gain competitive advantage.

Reason for doing the study

Companion diagnostics are an important aspect of the personalized treatment approach and are essential for predicting the therapeutic response to a particular drug. With increasing awareness among the population and rising incidences of cancer, companion diagnostics would become an essential factor for targeted therapeutic approach. More and more companies are developing targeted therapeutics products and companion diagnostics is an integral part of their strategy.

https://www.alliedmarketresearch.com

KEY BENEFITS

  • In-depth analysis of the companion diagnostic market by technology and indications give a clear idea of the scope of this market
  • Analysis of the market by geography would help in making region specific plans
  • Estimations for period of 2013 to 2020 have been given, taking into consideration the current market scenario and future trends, which would give a clearer picture of the potential of the market
  • Porters five force model and SWOT analysis would help in a deeper understanding of the market and help in making strategic decisions
  • Top factors impacting the market would help in making decisions for business development

KEY DELIVERABLES

MARKET BY INDICATIONS

  • Oncology
  • Cardiovascular
  • Central Nervous System
  • Auto immune & Inflammation
  • Virology
  • Others

MARKET BY TECHNOLOGY

  • Immunohistochemistry
  • Molecular diagnostics
    • In situ Hybridization
      • FISH
      • CISH
    • Real time PCR
    • Gene Sequencing

MARKET BY GEOGRAPHY

  • North America
  • Europe
  • Asia Pacific
  • LAMEA
* Pricing on the website is provided for single users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at +1-800-792-5285 or send an email to sales@alliedmarketresearch.com
Title/ Chapter Name

Chapter: 1. INTRODUCTION

1.1 Report description
1.2 Key market segments
1.3 Research methodology

1.3.1 Secondary research
1.3.2 Primary research
1.3.3 Analyst tools and models

Chapter: 2. EXECUTIVE SUMMARY

Chapter: 3. MARKET OVERVIEW 

3.1 Market Definition and Scope
3.2 Companion Diagnostics for Metabolic Diseases
3.3 Novel trends and technologies in companion diagnostics assay development
3.4 Companion diagnostics as a new trend in personalized medicine
3.5 Biomarkers market as basis for the companion diagnostics industry
3.6 Key Findings

3.6.1 Top Factors Impacting The Companion Diagnostic Market
3.6.2 Top Winning Strategies

3.7 Porter’s five forces analysis

3.7.1 High switching cost leads to higher bargaining power of suppliers
3.7.2 Highly differentiated products leads to lower bargaining power of buyers
3.7.3 Specificity of diagnostics lowers the threat of substitutes
3.7.4 Higher capital investment leads to lesser threat of entrants
3.7.5 Few competitors leads to low competition among players

3.8 Government Regulations

3.8.1 FDA regulations
3.8.2 Europe
3.8.3 Japan
3.8.4 China

3.9 Value Chain Analysis
3.10 Case Study
3.11 Drivers

3.11.1 Increased popularity of Personalized medicine
3.11.2 Increasing cases of adverse drug reactions(ADRs)
3.11.3 Increase in the Discovery of Biomarkers as drug targets.
3.11.4 Rising success of co-development drugs speedily approved by the FDA
3.11.5 Technological advancements
3.11.6 Rising incidences of diseases

3.12 Restraints

3.12.1 High Cost in research and development of drugs

3.12.1.1 Economic and scientific obstacles

3.12.2 Opportunities

3.12.2.1 Opportunities in treatment of neurodegenerative diseases
3.12.2.2 Companion diagnostics for hereditary mutations

Chapter: 4. GLOBAL COMPANION DIAGNOSTIC MARKET BY INDICATIONS

4.1 Oncology

4.1.1 Companion diagnostics oncology market by geography,
4.1.2 Breast Cancer

4.1.2.1 companion diagnostics breast cancer market by geography

4.1.3 Lung Cancer

4.1.3.1 companion diagnostics lung cancer market by geography

4.1.4 Colorectal Cancer

4.1.4.1 companion diagnostics Colorectal Cancer market by geography

4.1.5 Gastric cancer

 4.1.5.1 companion diagnostics Gastric Cancer market by geography

4.1.6 Melanomas

4.1.6.1 companion diagnostics Melanoma market by geography

4.2 Inflammation and Autoimmune diseases

4.2.1 Companion diagnostics inflammation market by geography

4.3 Companion diagnostics in cardiovascular diseases

4.3.1 Companion diagnostics tests for warfarin
4.3.2 Companion diagnostics cardiovascular market by geography

4.4 Companion diagnostics in CNS disorders

4.4.1 Companion diagnostics CNS market by geography

4.5 Companion diagnostics tests in virology diseases

4.5.1 Companion diagnostics virology market by geography

4.6 Others

4.6.1 Companion diagnostics others market by geography

Chapter: 5. GLOBAL COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY

5.1 Companion diagnostics technology market by geography
5.2 Immunohistochemistry

5.2.1 Companion diagnostics Immmunohistochemistry market by geography

5.3 Molecular Diagnostics

5.3.1 Companion diagnostics molecular diagnostics market by types
5.3.2 Companion diagnostics Molecular Diagnostics market by geography
5.3.3 In-situ Hybridization    

5.3.3.1 Fluorescent In-situ Hybridization(FISH)
5.3.3.2 CISH (Chromogenic In-Situ Hybridization)
5.3.3.3 Companion diagnostics In situ Hybridization market by geography

5.3.4 Real Time PCR

5.3.4.1 Companion diagnostics RT PCR market by geography

5.3.5 Gene Sequencing

5.3.5.1 Companion diagnostics Sequencing market by geography

5.3.6 Others

5.3.6.1 Others molecular companion diagnostics market by geography

Chapter: 6. GLOBAL COMPANION DIAGNOSTICS BY GEOGRAPHY

6.1 North America

6.1.1 Companion diagnostics North America market by indication

6.2 Europe

6.2.1 Companion diagnostics Europe market by indication

6.3 Asia Pacific

6.3.1 Companion diagnostics Asia Pacific market by indication

6.4 RoW

6.4.1 Companion diagnostics RoW market by indication

Chapter: 7. COMPANY PROFILES

7.1 Qiagen

7.1.1 Company Overview:
7.1.2 Company Snapshot
7.1.3 Business Performance
7.1.4 Strategy move and development

7.1.4.1    Principal strategies Collaborations
7.1.4.2    Secondary Strategies Approval

7.1.5 SWOT Analysis of Qiagen

7.2 Dako (Agilent Technologies)

7.2.1 Company Overview
7.2.2 Company Snapshot
7.2.3 Business Performance
7.2.4 Strategic Moves and Development

7.2.4.1  Principal strategies Collaboration
7.2.4.2  Secondary Strategies Approval

7.2.5 SWOT Analysis of Dako

7.3 Roche

7.3.1 Company overview
7.3.2 Company Snapshot
7.3.3 Business Performance
7.3.4 Strategies move and development
7.3.5 SWOT analysis of Roche

7.4 Abbott Laboratories, Inc.

7.4.1 Company Overview
7.4.2 Company Snapshot
7.4.3 Business Performance
7.4.4 Principal Strategies Collaboration
7.4.5 SWOT Analysis of Abbot

7.5 BioMerieux 

7.5.1 Company Overview
7.5.2 Company snapshot:
7.5.3 Business Performance
7.5.4 Strategies and development Approval
7.5.5 SWOT Analysis of BioMerieux, 

7.6 Ventana Medical Systems

7.6.1 Company Profile
7.6.2 Company Snapshot
7.6.3 Business Performance
7.6.4 Strategies and development  
7.6.5 SWOT Analysis of Ventana

7.7 Myriad Genetics, Inc.

7.7.1 Company Overview
7.7.2 Company snapshot
7.7.3 Business Performance
7.7.4 Strategies  and  development
7.7.5 SWOT Analysis of Myraid

7.8 Resonance Health Ltd

7.8.1 Company Overview
7.8.2 Company Snapshot
7.8.3 Strategies move and development
7.8.4 SWOT Analysis of Ferriscan

7.9 Leica Microsystems

7.9.1 Company overview
7.9.2 Company Snapshot
7.9.3 Strategies move and Development
7.9.4 SWOT Analysis of Leica Microsystems

7.10 Life Technologies

7.10.1 Company Overview
7.10.2 Company Snapshot
7.10.3 Business performance
7.10.4 Strategies move and Development
7.10.5 SWOT Analysis of Life Technologies

 

LIST OF TABLES

TABLE 1    GLOBAL COMPANION DIAGNOSTICS MARKET BY INDICATION, 2013-2020 ($MILLION)
TABLE 2    COMPANION DIAGNOSTICS INDICATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 3    GLOBAL COMPANION DIAGNOSTICS MARKET BY ONCOLOGY, 2013-2020, ($MILLION)
TABLE 4    COMPANION DIAGNOSTICS ONCOLOGY MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
TABLE 5    COMPANION DIAGNOSTICS BREAST CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 6    COMPANION DIAGNOSTICS LUNG CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 7    COMPANION DIAGNOSTICS COLORECTAL CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 8    COMPANION DIAGNOSTICS GASTRIC CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 9    COMPANION DIAGNOSTICS MELANOMA MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 10 COMPANION DIAGNOSTICS INFLAMMATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 11 COMPANION DIAGNOSTICS CARDIOVASCULAR MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 12 COMPANION DIAGNOSTICS CNS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 13 COMPANION DIAGNOSTICS VIROLOGY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 14 COMPANION DIAGNOSTICS OTHERS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 15 COMPANION DIAGNOSTICS TECHNOLOGY MARKET BY TECHNOLOGY 2013-2020 ($MILLION)
TABLE 16 COMPANION DIAGNOSTICS TECHNOLOGY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 17 COMPANION DIAGNOSTICS IMMMUNOHISTOCHEMISTRY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 18 COMPANION DIAGNOSTICS MOLECULAR DIAGNOSTICS MARKET BY TYPES 2013-2020 ($MILLION)
TABLE 19 COMPANION DIAGNOSTICS MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 20 COMPANION DIAGNOSTICS IN SITU HYBRIDIZATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 21 COMPANION DIAGNOSTICS RT PCR MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 22 COMPANION DIAGNOSTICS SEQUENCING MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 23 OTHERS MOLECULAR COMPANION DIAGNOSTICS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 24 COMPANION DIAGNOSTICS OTHERS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 25 COMPANION DIAGNOSTICS NORTH AMERICA MARKET, 2013-2020 ($MILLION)
TABLE 26 COMPANION DIAGNOSTICS EUROPE MARKET, 2013-2020 ($MILLION)
TABLE 27 COMPANION DIAGNOSTICS ASIA-PACIFIC MARKET, 2013-2020 ($MILLION)
TABLE 28 COMPANION DIAGNOSTICS ROW MARKET, 2013-2020 ($MILLION)
TABLE 29 QIAGEN SNAPSHOT
TABLE 30 DAKO COMPANY SNAPSHOT
TABLE 31 ROCHE COMPANY SNAPSHOT
TABLE 32 ABBOTT COMPANY SNAPSHOT
TABLE 33 BIOMERIEUX COMPANY SNAPSHOT
TABLE 34 VENTANA COMPANY SNAPSHOT
TABLE 35 MYRIAD COMPANY SNAPSHOT
TABLE 36 RESONANCE COMPANY SNAPSHOT
TABLE 37 LEICA COMPANY SNAPSHOT
TABLE 38 LIFE TECHNOLOGIES COMPANY SNAPSHOT

 

LIST OF FIGURES

FIG.1 COMPANION DIAGNOSTICS AS A NEW TREND IN PERSONALIZED MEDICINE
FIG.2 EFFECTIVENESS OF COMPANION DIAGNOSTICS IN LUNG CANCER PATIENTS
FIG.3 LIST BIOMARKERS AND THE COMPANION DIAGNOSTICS FOR VARIOUS DISEASES
FIG.4 TOP FACTORS IMPACTING THE COMPANION DIAGNOSTIC MARKET
FIG.5 TOP WINNING STRATEGIES
FIG.6 VALUE CHAIN ANALYSIS
FIG.7 FINANCIAL REVENUES BY BUSINESS UNITS (2013)
FIG.8 FINANCIAL REVENUES BY GEOGRAPHY(2013)
FIG.9 SWOT ANALYSIS OF QIAGEN
FIG.10 FINANCIAL REVENUE OF DAKO, BY SEGMENT (2012)
FIG.11 SWOT ANALYSIS OF DAKO
FIG.12 FINANCIAL REVENUE OF DAKO, BY SEGMENT
FIG.13 FINANCIAL REVENUE OF DAKO, BY GEOGRAPHY
FIG.14 SWOT ANALYSIS OF ROCHE
FIG.15 REVENUE BY BUSINESS SEGMENTS
FIG.16 REVENUE BY GEOGRAPHY
FIG.17 SWOT ANALYSIS OF ABBOTT
FIG.18 FINANCIAL REVENUES BY GEOGRAPHY
FIG.19 FINANCIAL REVENUES BY TECHNOLOGY
FIG.20 SWOT ANALYSIS OF BIOMERIEUX
FIG.21 SWOT ANALYSIS OF VENTANA
FIG.22 REVENUE BY DIAGNOSTIC TYPE
FIG.23 SWOT ANALYSIS OF MYRAID
FIG.24 SWOT ANALYSIS OF FERRISCAN
FIG.25 SWOT ANALYSIS OF LEICA MICROSYSTEMS
FIG.26 REVENUE BY END MARKETS
FIG.27 SWOT ANALYSIS OF LIFE TECHNOLOGIES

Companion diagnostics are used to identify patients most likely to benefit from treatment with a particular drug. This market is an emerging market with very few approved products currently available. The market is dependent on research and development of new drugs and discovery of biomarkers. Increase in research and development of targeted therapies and discovery of new biomarkers for various conditions is driving growth of this market. The challenge to this market is co-ordination of co-development of drug and diagnostic. The global companion diagnostics market is segmented into three categories viz. cancer biomarkers, technology and geography.

This market research report is an effort to provide the clear picture of the state of the market and sub markets over the next seven years. The report provides micro level analysis of the factors affecting the market, key market trends and industry drives and challenges for the better understanding of the market structure. The presentation of the market dynamics, competitive scenario and developments will enable marketers to aptly design their growth strategies and have competitive edge. Moreover, assessment of the top investment pockets and winning strategies will help in channelizing their investments in the right directions to garner better proceeds.

SINGLE USER
GROUP LICENSE
SITE LICENSE
GLOBAL LICENSE
$4515
$5325
$7350
$10680
LICENSE INFO
Users/Sharing
Restricted to one authorized user

Limited to 5 authorized users

Up to 25 users


unlimited within company / enterprise
Copy/Paste
Allowed up to 20% of the content
Allowed up to 25% of the content
Allowed up to 50% of the content
allowed 100%

Printing
One print only

Five Prints

Unlimited for internal use
Unlimited for internal use
Delivery Formats
ADDED BENIFITS
20% Free customization (Pre-sale)
16 Analyst hour support (Post Sale)
40 Analyst hour support (Post Sale)
160 hours of mini-consult
Free quarterly industry update
Free report on update (within 180 days)
MULTIPLE PURCHASE
Complimentary report with 2 reports
Complimentary report with 3 reports
Subscription Model
Have questions ?
connect
Need to add more ?
request

Single User
$4515
Group User
$5325
Site User
$7350
Global User
$10680
buy now

Discount will be applied in cart.
First time buyer ?
Check offers and discount
on this report
GET DISCOUNT
Need More Information
phone_n +1-503-894-6022

Help AMR help@alliedmarketresearch.com
Or
Send Enquiry
WHY ALLIED MARKET RESEARCH?
Infallible Methodology
To ensure high level data integrity, accurate analysis and impeccable forecasts
ANALYST SUPPORT
For complete satisfaction
CUSTOMIZATION
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET
Targeted market view to eliminate redundant information to provide valued information and save time of the reader
RECENTLY VIEWED REPORTS
get_n
SIMILAR MARKET REPORTS
  • ...
    Neem extract refers to pastes, oils, cakes, powders and other related products that are obtained through barks, leaves, fruits and seeds of neem tree. These does not include finished neem products such as personal care, animal care, fertilizers among others.
    Apr 2016 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Ebola virus disease (EVD), also known as Ebola hemorrhagic fever (EHF), results from Ebola virus and three other closely related viruses in the genes (group of related viruses) of ebola virus. Initial symptoms of this disease include sore throat, headaches, fever and muscles pain. It causes hemorrhagic fever that leads to internal or external bleeding. EVD is widely prevalent in Central and Western Africa, and near tropical rainforests.
    Sep 2014 | Price: $2625(SU) €0(SU) £0(SU) | View Details >>
  • ...
    The Continuous Glucose Monitoring Systems (CGMS) market has emerged as a promising diabetes management tool for monitoring all types of diabetic patients. Replacement/repeat sales of components such as sensors drive the growth of the CGMS market. Continuous glucose monitoring finds its application within the patients suffering from hypo and hyperglycemic conditions.
    Jun 2015 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
ON DEMAND REPORTS
  • ...
    Obesity is a medical term used when excessive accumulation of fat occurs in the body. It may have numerous adverse effects on health, which increases the chances of occurrence of diseases and ultimately reduces life expectancy of an individual. Some of the diseases to which an obese individual is prone include type II diabetes, heart diseases, osteoarthritis and even certain types of cancer. One-third of adults in the U.S are obese. The rising pace of obesity and chronic diseases is creating the need for weight loss programs and obesity management.
    Aug 2016 | View Details >>
  • ...
    Hyperspectral Imaging (HSI) is an imaging technique for collection and processing information across electromagnetic spectrum. The prime function of HSI is to form a spectrum of each pixel of image to study objects. The need to have a prior knowledge about a sample to be studied is eliminated using HSI technique. This technique is used to track development of crops, diagnosis of retinopathy, and identify & detect contaminants in food. HSI technique plays significant role in research areas, such as nano-toxicology and nano-drug delivery.
    Aug 2016 | View Details >>
  • ...
    Immunoassay is a test conducted to determine concentration of macromolecule in a solution using antibody or immunoglobulin. The macromolecule detected is known as analyte.
    Aug 2016 | View Details >>
  • ...
    Laparoscopy is a minimally invasive operation in which abdominal or pelvic surgery is performed through a small incision. It has several advantages over laparotomy, which requires larger incisions. Laparoscopy uses TV images to examine and diagnose the condition of a disease or to carry out surgery. A rise in the obese population has resulted in laparoscopic surgeries being popularly used for weight reduction (bariatric surgeries). In-depth analysis of the global laparoscopy devices market focuses on various aspects of the market such as market trends, market drivers, restraints and opportunities.
    Aug 2016 | View Details >>